机构：[1]Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000[2]Department of Clinical College, Xiangtan Medicine and Health Vocational College, Xiangtan, Hunan 411104[3]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 50011临床科室肿瘤内科河北医科大学第四医院[4]Department of Emergency,First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China[5]Precision Medicine Center, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China
Cervical cancer (CC) is one of the most prevalent types of cancer affecting females worldwide. However, the molecular mechanisms underlying the development and progression of CC remains to be elucidated. Taking the high incidence and mortality rates amongst women into consideration, the identification of novel biomarkers to prevent CC is of great significance and required to improve diagnosis. Using three raw microarray datasets from the Gene Expression Omnibus database, 188 differentially expressed genes (DEGs) were identified. Gene Ontology and pathway analyses were performed on the DEGs. Through protein-protein interaction network construction and module analysis, eight hub genes [cell division cycle 6, cyclin-dependent kinase 1 (CDK1), cell division control protein 45, budding uninhibited by benzimidazoles 1 (BUB1), DNA topoisomerase II alpha (TOP2A) and minichromosome maintenance complex component 4, CCNB2 and CCNB1] were identified, but only TOP2A was considered a prognostic factor in survival analysis. There were strong positive correlations between TOP2A and BUB1 (P<0.0001, rs=0.635), CDK1 (P<0.0001, rs=0.511), centromere protein F (CENPF) (P<0.0001, rs=0.677), Rac GTPase activating protein 1 (RACGAP1) (P<0.0001, rs=0.612), F-box protein 5 (FBXO5) (P<0.0001, rs=0.585) and BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) (P<0.0001, rs=0.584). Additionally, BUB1, CDK1, CENPF, RACGAP1, FBXO5 and BUB1B are all potentially suitable candidate targets for the diagnosis and treatment of CC. In conclusion, the present study identified TOP2A as a potential tumor oncogene and a biomarker for the prognosis of CC.
基金：
This study was partially supported by the National Natural Science Foundation of China (grant no. 81702580) and the Natural Science Foundation of Jiangxi Province (grant nos. 2017ACB21066 and 20171BBG70051).
第一作者机构：[1]Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000
共同第一作者：
通讯作者：
通讯机构：[1]Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000[5]Precision Medicine Center, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China[*1]Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, 23 Qingnian Road, Ganzhou, Jiangxi 341000, P.R. China
推荐引用方式(GB/T 7714)：
Zhao Qinfei,Li Huaying,Zhu Longyu,et al.Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer[J].BIOMEDICAL REPORTS.2020,13(4):doi:10.3892/br.2020.1328.
APA：
Zhao, Qinfei,Li, Huaying,Zhu, Longyu,Hu, Suping,Xi, Xuxiang...&Zhong, Tianyu.(2020).Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer.BIOMEDICAL REPORTS,13,(4)
MLA：
Zhao, Qinfei,et al."Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer".BIOMEDICAL REPORTS 13..4(2020)
